甲亢患者口服卡比马唑和甲巯咪唑后甲巯咪唑的药代动力学。
The pharmacokinetics of methimazole after oral administration of carbimazole and methimazole, in hyperthyroid patients.
作者信息
Skellern G G, Knight B I, Low C K, Alexander W D, McLarty D G, Kalk W J
出版信息
Br J Clin Pharmacol. 1980 Feb;9(2):137-43. doi: 10.1111/j.1365-2125.1980.tb05823.x.
Abstract
1 Methimazole plasma concentrations were measured in two groups of hyperthyroid subjects after the oral administration of either carbimazole or methimazole. 2 With the HPLC method it was also possible to measure the concentration of a methimazole metabolite, 3-methyl-2-thiohydantoin in one patient. 3 Large interindividual differences were observed, especially within the carbimazole group. 4 Incomplete absorption of carbimazole could explain particular high apparent volumes of distribution and apparent clearances.
摘要
- 在两组甲状腺功能亢进患者口服卡比马唑或甲巯咪唑后，测量了甲巯咪唑的血浆浓度。2. 采用高效液相色谱法还能够测量一名患者中甲巯咪唑代谢物3 - 甲基 - 2 - 硫代乙内酰脲的浓度。3. 观察到个体间存在较大差异，尤其是在卡比马唑组中。4. 卡比马唑吸收不完全可解释分布表观容积和表观清除率特别高的原因。
相似文献
1
The pharmacokinetics of methimazole after oral administration of carbimazole and methimazole, in hyperthyroid patients.甲亢患者口服卡比马唑和甲巯咪唑后甲巯咪唑的药代动力学。
Br J Clin Pharmacol. 1980 Feb;9(2):137-43. doi: 10.1111/j.1365-2125.1980.tb05823.x.
2
The pharmacokinetics of methimazole in pregnant patients after oral administration of carbimazole.卡比马唑口服给药后孕妇中甲巯咪唑的药代动力学。
Br J Clin Pharmacol. 1980 Feb;9(2):145-7. doi: 10.1111/j.1365-2125.1980.tb05824.x.
3
Comparative bioavailability of carbimazole and methimazole.卡比马唑和甲巯咪唑的相对生物利用度。
Int J Clin Pharmacol Ther Toxicol. 1983 Oct;21(10):505-10.
4
Pharmacokinetics of methimazole in normal subjects and hyperthyroid patients.甲巯咪唑在正常受试者和甲状腺功能亢进患者中的药代动力学。
Endocrinol Jpn. 1986 Oct;33(5):605-15. doi: 10.1507/endocrj1954.33.605.
5
Pharmacokinetics of controlled-release carbimazole tablets support once daily dosing in cats.控释卡比马唑片在猫体内的药代动力学支持每日一次给药。
J Vet Pharmacol Ther. 2008 Jun;31(3):213-9. doi: 10.1111/j.1365-2885.2008.00949.x.
6
The efficacy and safety of a novel lipophilic formulation of methimazole for the once daily transdermal treatment of cats with hyperthyroidism.一种新型亲脂性甲巯咪唑制剂经皮治疗甲状腺功能亢进症猫每日一次的疗效和安全性。
J Vet Intern Med. 2011 Nov-Dec;25(6):1357-65. doi: 10.1111/j.1939-1676.2011.00799.x. Epub 2011 Sep 28.
7
Intrathyroidal iodide binding rates and plasma methimazole concentrations in hyperthyroid patients on small doses of carbimazole.小剂量卡比马唑治疗的甲状腺功能亢进患者的甲状腺内碘结合率和血浆甲巯咪唑浓度
Br J Clin Pharmacol. 1981 Sep;12(3):315-8. doi: 10.1111/j.1365-2125.1981.tb01219.x.
8
Identification of 3-methyl-2-thiohydantoin, a metabolite of carbimazole, in man.
Xenobiotica. 1977 Apr;7(4):247-53. doi: 10.3109/00498257709035782.
9
Comparison of the disposition of carbimazole and methimazole in clinically normal cats.
Res Vet Sci. 1993 May;54(3):351-5. doi: 10.1016/0034-5288(93)90134-2.
10
The pharmacokinetics of methimazole in a novel lipophilic formulation administered transdermally to healthy cats.甲巯咪唑新型亲脂性制剂经皮给药于健康猫的药代动力学。
N Z Vet J. 2014 Jul;62(4):208-13. doi: 10.1080/00480169.2013.875990. Epub 2014 Feb 28.
引用本文的文献
1
The Protective Effect of Turmeric against Carbimazole Induced Toxicity in Male Rats.姜黄对卡比马唑诱导雄性大鼠毒性的保护作用。
Arch Razi Inst. 2022 Dec 31;77(6):2081-2087. doi: 10.22092/ARI.2022.358130.2156. eCollection 2022 Dec.
2
Clinically practical pharmacometrics computer model to evaluate and personalize pharmacotherapy in pediatric rare diseases: application to Graves' disease.用于评估和个性化儿科罕见病药物治疗的临床实用药代动力学计算机模型：在格雷夫斯病中的应用
Front Med (Lausanne). 2023 May 3;10:1099470. doi: 10.3389/fmed.2023.1099470. eCollection 2023.
3
MATERNAL GRAVES DISEASE AND ABNORMAL CYP2D6 GENOTYPE WITH FETAL HYPERTHYROIDISM.患有格雷夫斯病和CYP2D6基因异常的母亲与胎儿甲状腺功能亢进症
AACE Clin Case Rep. 2020 Apr 3;6(4):e161-e164. doi: 10.4158/ACCR-2019-0517. eCollection 2020 Jul-Aug.
4
Associations of HLA genotypes with antithyroid drug-induced agranulocytosis: A systematic review and meta-analysis of pharmacogenomics studies.HLA 基因型与抗甲状腺药物诱导的粒细胞缺乏症的关联：药物基因组学研究的系统评价和荟萃分析。
Br J Clin Pharmacol. 2019 Sep;85(9):1878-1887. doi: 10.1111/bcp.13989. Epub 2019 Jul 7.
5
Antithyroid Drug-Induced Agranulocytosis: State of the Art on Diagnosis and Management.抗甲状腺药物所致粒细胞缺乏症：诊断与管理的最新进展
Drugs R D. 2017 Mar;17(1):91-96. doi: 10.1007/s40268-017-0172-1.
6
Influence of Carbimazole on Serum Levels and Haemodynamic Effects of Digoxin.
Clin Drug Investig. 1997 Jun;13(6):350-4. doi: 10.2165/00044011-199713060-00008.
7
Estimating Margin of Exposure to Thyroid Peroxidase Inhibitors Using High-Throughput in vitro Data, High-Throughput Exposure Modeling, and Physiologically Based Pharmacokinetic/Pharmacodynamic Modeling.利用高通量体外数据、高通量暴露建模和基于生理的药代动力学/药效学建模估算甲状腺过氧化物酶抑制剂的暴露量边际
Toxicol Sci. 2016 May;151(1):57-70. doi: 10.1093/toxsci/kfw022. Epub 2016 Feb 10.
8
The metabolism of methimazole in pregnancy.妊娠期间甲巯咪唑的代谢。
Br J Clin Pharmacol. 1980 Sep;10(3):314. doi: 10.1111/j.1365-2125.1980.tb01766.x.
9
The pharmacokinetics of methimazole in pregnant patients after oral administration of carbimazole.卡比马唑口服给药后孕妇中甲巯咪唑的药代动力学。
Br J Clin Pharmacol. 1980 Feb;9(2):145-7. doi: 10.1111/j.1365-2125.1980.tb05824.x.
10
Intrathyroidal iodide binding rates and plasma methimazole concentrations in hyperthyroid patients on small doses of carbimazole.小剂量卡比马唑治疗的甲状腺功能亢进患者的甲状腺内碘结合率和血浆甲巯咪唑浓度
Br J Clin Pharmacol. 1981 Sep;12(3):315-8. doi: 10.1111/j.1365-2125.1981.tb01219.x.
本文引用的文献
1
Antithyroid substances. 2. Some mercaptoglyoxalines, mercaptothiazoles and thiohydantoins.抗甲状腺物质。2. 一些巯基乙二醛啉、巯基噻唑和硫代乙内酰脲。
Biochem J. 1951 Jun;49(1):125-8. doi: 10.1042/bj0490125.
2
A new route to the imidazole-2-thiones from 2-thiohydantoins. Implications in the study of ergothioneine.一种从2-硫代乙内酰脲合成咪唑-2-硫酮的新途径。对麦角硫因研究的启示。
Biochem J. 1968 Sep;109(2):209-15. doi: 10.1042/bj1090209.
3
Development and comparison of thin-layer chromatographic and gas-liquid chromatographic methods for measurement of methimazole in rat urine.
J Chromatogr. 1970 Dec;53(2):285-91. doi: 10.1016/s0021-9673(01)98469-9.
4
Proceedings: Changes in drug metabolizing ability in thyroid disease.会议论文：甲状腺疾病中药物代谢能力的变化
Br J Pharmacol. 1973 Sep;49(1):156P-157P.
5
Serum propylthiouracil: determination by a direct colorimetric procedure.
Clin Chem. 1972 Nov;18(11):1373-5.
6
Metabolism of 35S-labelled antithyroid drugs in man.人体中35S标记抗甲状腺药物的代谢
Br Med J. 1969 May 3;2(5652):290-1. doi: 10.1136/bmj.2.5652.290.
7
The acclumulation of 35 S-antithyroid drugs by the thyroid gland.
J Clin Endocrinol Metab. 1972 May;34(5):847-51. doi: 10.1210/jcem-34-5-847.
8
Methimazole: its absorption and excretion in man and tissue distribution in rats.甲巯咪唑：其在人体中的吸收与排泄及在大鼠体内的组织分布
J Clin Endocrinol Metab. 1971 Aug;33(2):182-5. doi: 10.1210/jcem-33-2-182.
9
Altered plasma half-lives of antipyrine, propylthiouracil, and methimazole in thyroid dysfunction.甲状腺功能障碍时安替比林、丙硫氧嘧啶和甲巯咪唑的血浆半衰期改变。
Clin Pharmacol Ther. 1975 Jan;17(1):48-56. doi: 10.1002/cpt197517148.
10
Identification of 3-methyl-2-thiohydantoin, a metabolite of carbimazole, in man.
Xenobiotica. 1977 Apr;7(4):247-53. doi: 10.3109/00498257709035782.
Zotero 插件